| P2093 | author name string | H L DuPont | |
| P2860 | cites work | Diversity of the human intestinal microbial flora | Q24544241 |
| | The gut flora as a forgotten organ | Q24550824 |
| | Linking long-term dietary patterns with gut microbial enterotypes | Q24609914 |
| | The role of gut microbiota in immune homeostasis and autoimmunity | Q26860722 |
| | Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases | Q28131810 |
| | The gut microbiota--masters of host development and physiology | Q28286102 |
| | Gut Microbiota in Health and Disease | Q29616812 |
| | Functional interactions between the gut microbiota and host metabolism | Q29616815 |
| | NF-kappaB: a key role in inflammatory diseases | Q29617726 |
| | Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. | Q31142368 |
| | The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. | Q33670800 |
| | In vitro activity and fecal concentration of rifaximin after oral administration | Q33980321 |
| | Gut microbes, diet, and cancer. | Q34000541 |
| | Bile acids improve the antimicrobial effect of rifaximin | Q34108534 |
| | Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial | Q34519193 |
| | Lysophosphatidylcholine increases rat ileal permeability to macromolecules | Q34526031 |
| | Therapy of travelers' diarrhea with rifaximin on various continents | Q34534555 |
| | Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci | Q34552369 |
| | Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone | Q34578062 |
| | Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative | Q34729751 |
| | Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea | Q34754721 |
| | Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis | Q34901665 |
| | Gut microbiota, immunity, and disease: a complex relationship | Q35195785 |
| | Brain-gut-microbe communication in health and disease | Q35597520 |
| | Rifaximin: in vitro and in vivo antibacterial activity--a review | Q36108484 |
| | Systemic pharmacokinetics of rifaximin in volunteers with shigellosis | Q36482910 |
| | Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ | Q36886503 |
| | The gut microbiome: the role of a virtual organ in the endocrinology of the host. | Q38119938 |
| | Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei | Q39756592 |
| | Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles | Q39783194 |
| | Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin | Q40375271 |
| | In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea | Q42730284 |
| | Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora | Q43215557 |
| | In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. | Q43627883 |
| | Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. | Q45573898 |
| | Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations | Q46604531 |
| | Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship | Q46835462 |
| | The effect of rifaximin on gut flora and Staphylococcus resistance. | Q54263702 |
| | Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae | Q57932930 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | review article | Q7318358 |
| P304 | page(s) | 3-10 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Review article: the antimicrobial effects of rifaximin on the gut microbiota | |
| P478 | volume | 43 Suppl 1 | |